Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 11 articles:
HTML format

Single Articles

    July 2021
  1. EKHOLM M, Wallen NH, Brinck J, Jorneskog G, et al
    Altered vascular reactivity to circulating angiotensin II in familial hypercholesterolemia.
    J Cardiovasc Pharmacol. 2021 Jul 8. pii: 00005344-900000000-98174.
    PubMed     Abstract available

    May 2021
  2. JIN M, Meng F, Yang W, Liang L, et al
    The efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis.
    J Cardiovasc Pharmacol. 2021 May 31. pii: 00005344-900000000-98211.
    PubMed     Abstract available

    November 2020
  3. HU H, Cheng J, Lin S, Wang S, et al
    Calcified Aortic Valve Disease in Patients With Familial Hypercholesterolemia.
    J Cardiovasc Pharmacol. 2020;76:506-513.
    PubMed     Abstract available

    February 2020
  4. LIU N, Yang G, Liu Y, Hu M, et al
    Effect of Cytochrome P450 7A1 (CYP7A1) Polymorphism on Lipid Responses to Simvastatin Treatment.
    J Cardiovasc Pharmacol. 2020;75:168-173.
    PubMed     Abstract available

  5. SHI G, Liu D, Zhou B, Liu Y, et al
    Ginsenoside Rb1 Alleviates Oxidative Low-Density Lipoprotein-Induced Vascular Endothelium Senescence via the SIRT1/Beclin-1/Autophagy Axis.
    J Cardiovasc Pharmacol. 2020;75:155-167.
    PubMed     Abstract available

    January 2019
  6. CHENG W, Jia X, Li J, Cheng W, et al
    Relationships of Statins Therapy and Hyperlipidemia with the Incidence, Rupture, Post-repair Mortality and All-cause Mortality of Abdominal Aortic Aneurysm and Cerebral Aneurysm: A Meta-analysis and Systematic Review.
    J Cardiovasc Pharmacol. 2019 Jan 25. doi: 10.1097/FJC.0000000000000653.
    PubMed     Abstract available

    June 2018

  7. CaMKII Activation Promotes Cardiac Electrical Remodeling and Increases the Susceptibility to Arrhythmia Induction in High-fat Diet-Fed Mice With Hyperlipidemia Conditions: Erratum.
    J Cardiovasc Pharmacol. 2018;71:387.

    March 2018
  8. BISGAIER CL, Oniciu DC, Srivastava RAK
    Comparative Evaluation of Gemcabene and PPAR Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2018 Mar 21. doi: 10.1097/FJC.0000000000000580.
    PubMed     Abstract available

    August 2017
  9. JOHNSTON TP, Korolenko TA, Sahebkar A
    The P-407-Induced Mouse Model of Dose-Controlled Hyperlipidemia and Atherosclerosis: Twenty-five Years Later.
    J Cardiovasc Pharmacol. 2017 Aug 4. doi: 10.1097/FJC.0000000000000522.
    PubMed     Abstract available

    July 2017
  10. ZHONG P, Quan D, Huang Y, Huang H, et al
    CaMKII activation promotes cardiac electrical remodeling and increases the susceptibility to arrhythmia induction in high fat diet-fed mice with hyperlipidemia conditions.
    J Cardiovasc Pharmacol. 2017 Jul 4. doi: 10.1097/FJC.0000000000000512.
    PubMed     Abstract available

    February 2016
  11. UPPUGUNDURI CR, George M
    Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.
    J Cardiovasc Pharmacol. 2016;67:191-2.

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.